Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1996-6-24
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0002-9343
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
100
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
243-4
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:8629663-Androgen Antagonists,
pubmed-meshheading:8629663-Flutamide,
pubmed-meshheading:8629663-Humans,
pubmed-meshheading:8629663-Male,
pubmed-meshheading:8629663-Prostate-Specific Antigen,
pubmed-meshheading:8629663-Prostatic Neoplasms,
pubmed-meshheading:8629663-Receptors, Androgen,
pubmed-meshheading:8629663-Treatment Failure
|
pubmed:year |
1996
|
pubmed:articleTitle |
Therapeutic options in patients with hormone-refractory prostate cancer.
|
pubmed:publicationType |
Letter,
Comment
|